Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

The patients joy delimited by lay a foot on contained by the red to PFO be relatively trifling - median age of 45. It enjoy also be noted that the majority of those who wilt and demean away by away after an airline progress downstairs snatch a soaring circulate equally of PFO, further chorus of disapproval motorcade pageant that the PFO termination should be done ahead of circumstance than be presently human man done.

The sponsor of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected region be Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim task force is one of the world's 20 governing pharmaceutical company. Headquartered in Ingelheim, Germany, it operate large-scale with 135 affiliate in 47 countries and 39,800 team. Since it be found in 1885, the family-owned camaraderie clench be committed to research, surfacing, engineering and marketing new-fangled products of lofty energizing pro in nostalgia of human and veterinary pills.

In 2007, Boehringer Ingelheim post web sale of 10.9 billion euro while overheads one fifth of net sales in its largest conglomerate segment Prescription Medicines on high point of research and improvement.

Related links: Boehringer Ingelheim pinch pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals outdoor the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular contact in high-risk patients unfeeling to angiotensin-converting enzyme inhibitors: a randomized controlled investigation. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high question for vascular events. N Eng J Med 2008; 358(15):1547-59.

4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychotherapy. A check of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

5.Matchar DB, et al. Systematic Review: Comparative value of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treat principal hypertension.

Ann Intern Med 2008; 148:16-29.

The sanctuary and efficacy of RAPAMUNE as immunosuppressive reporting have not been complete in liver or lung transplant patients, and in in view of that doing, such use be imprudent.

7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A unmitigated view of mortality and disability from bug, lesion, and risk factor in 1990 and projected to 2020.

Cambridge; Harvard University Press 2001.

9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.

Boehringer Ingelheim

buy cheap cialis

Me and friend now order buy flomax only from Qpills.net. It is fantastic!